Scienture Holdings Reports Revenue Growth to $343,639, Net Loss Reduced by 58%

Scienture Holdings, Inc. (formerly TRxADE Health, Inc.) reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated revenues of $343,639 for the three months ended June 30, 2026, a notable increase from zero revenues in the same period last year. For the six months ended June 30, 2026, revenues reached $399,964, compared to $10,258 in the prior year. This growth is attributed to the commercialization of its product ARBLI™ (SCN-102), an oral liquid formulation of losartan potassium, which received FDA approval in March 2025.

Despite the revenue increase, Scienture reported a net loss of $2,822,371 for the three months ended June 30, 2026, a 58% reduction from the net loss of $6,720,573 in the same quarter of 2025. For the six-month period, the net loss was $6,224,635, down from $9,784,570 in the previous year. The decrease in losses is primarily due to lower operating expenses, which fell by 41% to $3,035,512 in the second quarter of 2026, compared to $5,157,906 in the same quarter of 2025. The company attributed this reduction to decreased wage and salary expenses, as well as lower general and administrative costs following the divestiture of legacy subsidiaries.

In terms of strategic developments, Scienture has focused on enhancing its operational efficiency and product offerings. The company has streamlined its operations by divesting from legacy subsidiaries and concentrating on its core pharmaceutical business. As of June 30, 2026, the company reported total assets of $87,734,007, an increase from $84,178,330 at the end of 2025. The company’s cash and cash equivalents also rose to $8,188,140, up from $6,662,008, bolstered by financing activities that included proceeds from a loan payable.

Operationally, Scienture has made strides in its product pipeline, with ARBLI™ being the first FDA-approved ready-to-use oral liquid losartan in the U.S. market. The company is also preparing for the launch of its second product, REZENOPY™ (SCN-110), a naloxone nasal spray, which is expected to be commercialized in August 2026. The company’s research and development expenses increased to $1,166,605 for the three months ended June 30, 2026, reflecting ongoing investments in its product candidates, including SCN-104 and SCN-106.

Looking ahead, Scienture's management expressed optimism about the company's future, citing plans to continue generating revenue from ARBLI™ and the anticipated launch of REZENOPY™. However, the company also acknowledged the need for additional capital to support ongoing operations and product development. As of June 30, 2026, Scienture had an accumulated deficit of $86,775,872, raising concerns about its ability to continue as a going concern without securing further financing. The company plans to explore various funding options, including equity and debt financing, to support its growth strategy and operational needs.